Company / SG&A Expense
Relay Therapeutics, Inc. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$56.7M
FY2025
5-year range
$13.7M / $76.6M
FY2021-FY2025
Trend
-26.0%
vs FY2024
Sector context
#150 of 213
Health Care
What the data says
At $57M, Relay Therapeutics, Inc.'s sg&a expense ranks #64 of 213 in the Health Care sector. Improved from $75M to $57M over the past 2 years.
Based on SEC 10-K filings.
$57M in FY2025 with a 5-year CAGR of +32.8%.
Improved from $75M to $57M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +13.7%
- 5-Year CAGR
- +32.8%
- 10-Year CAGR
- -
Sector benchmark
#64 of 213 in Health CareTop 30% of 213This company $56.7M Sector average $722.3M
▼
-92.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +32.8%, indicating consistent growth.
- In FY2025, sg&a expense decreased 26.0% year-over-year.
- Ranks #150 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $56.7M | -26.0% |
| FY2024 | $76.6M | +2.2% |
| FY2023 | $75.0M | +94.2% |
| FY2022 | $38.6M | +180.8% |
| FY2021 | $13.7M | +0.0% |
| FY2020 | $13.7M | +0.0% |
| FY2019 | $13.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026